US 12,281,099 B2
Isoindolinone substituted indoles and derivatives as RAS inhibitors
Andreas Mantoulidis, Vienna (AT); Andreas Gollner, Vienna (AT); Dirk Kessler, Vienna (AT); Laetitia Janine Martin, Saint Louis (FR); and Harald Weinstabl, Vienna (AT)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Appl. No. 17/430,011
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
PCT Filed Feb. 25, 2020, PCT No. PCT/EP2020/054897
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/173935, PCT Pub. Date Sep. 3, 2020.
Claims priority of application No. 19159299 (EP), filed on Feb. 26, 2019.
Prior Publication US 2022/0144810 A1, May 12, 2022
Int. Cl. C07D 403/04 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)
CPC C07D 403/04 (2013.01) [A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)] 3 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a salt thereof.